Guidance: Centres of Excellence for Regulatory Science and Innovation (CERSIs)

Annual Report of the Human Medicines Regulations 2012 Advisory Bodies – the Commission on Human Medicines (CHM) and the British Pharmacopoeia Commission.

There is a small increase in the risk of Guillain-Barré syndrome following vaccination with Abrysvo (Pfizer respiratory syncytial virus (RSV) vaccine) and Arexvy (GSK RSV vaccine) in adults aged 60 years and older. Healthcare professionals should advise all recipients of Abrysvo and Arexvy that they should be alert to signs and symptoms of Guillain-Barré syndrome and, if they occur, to seek immediate medical attention as it requires urgent treatment in hospital.

How to conform with the legal requirements for placing medical devices on the market.

Guidance on the various types of modifications that can be made to a clinical trial approval.

Professor Benger’s leadership comes at a pivotal time as the MHRA and NICE deepen collaboration

How to get information including patient information leaflets (PILs), details on how the medicine can be used (SmPCs) and scientific reports (PARs).